172 related articles for article (PubMed ID: 36805869)
1. Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry.
Lin W; Aluicio-Sarduy E; Houson HA; Barnhart TE; Tekin V; Jeffery JJ; Weichmann AM; Barrett KE; Lapi SE; Engle JW
Nucl Med Biol; 2023; 118-119():108329. PubMed ID: 36805869
[TBL] [Abstract][Full Text] [Related]
2. PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68.
Houson HA; Tekin V; Lin W; Aluicio-Sarduy E; Engle JW; Lapi SE
Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559218
[TBL] [Abstract][Full Text] [Related]
3. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
4. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
5. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
6. Proof of Therapeutic Efficacy of a
Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
[TBL] [Abstract][Full Text] [Related]
7. Development of [
Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
[TBL] [Abstract][Full Text] [Related]
8. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.
He T; Wang M; Wang H; Tan H; Tang Y; Smith E; Wu Z; Liao W; Hu S; Li Z
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2199-2207. PubMed ID: 31264168
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cobalt-labeled octreotide analogs for molecular imaging and auger electron-based radionuclide therapy.
Thisgaard H; Olsen BB; Dam JH; Bollen P; Mollenhauer J; Høilund-Carlsen PF
J Nucl Med; 2014 Aug; 55(8):1311-6. PubMed ID: 24876207
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
García-Garayoa E; Bläuenstein P; Bruehlmeier M; Blanc A; Iterbeke K; Conrath P; Tourwé D; Schubiger PA
J Nucl Med; 2002 Mar; 43(3):374-83. PubMed ID: 11884498
[TBL] [Abstract][Full Text] [Related]
12. Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
Janssen PJ; de Visser M; Verwijnen SM; Bernard BF; Srinivasan A; Erion JL; Breeman WA; Vulto AG; Krenning EP; de Jong M
Cancer Biother Radiopharm; 2007 Jun; 22(3):374-81. PubMed ID: 17651043
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
14. (18)F- and (68)Ga-Labeled Neurotensin Peptides for PET Imaging of Neurotensin Receptor 1.
Maschauer S; Einsiedel J; Hübner H; Gmeiner P; Prante O
J Med Chem; 2016 Jul; 59(13):6480-92. PubMed ID: 27336295
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
16. Preclinical PET Imaging of NTSR-1-Positive Tumors with
Li D; Minnix M; Allen R; Bading J; Chea J; Wong P; Bowles N; Poku E; Shively JE
Cancer Biother Radiopharm; 2021 Oct; 36(8):651-661. PubMed ID: 32822229
[No Abstract] [Full Text] [Related]
17. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of [
Baun C; Dam JH; Hildebrandt MG; Ewald JD; Kristensen BW; Gammelsrød VS; Olsen BB; Thisgaard H
Sci Rep; 2023 Nov; 13(1):18837. PubMed ID: 37914790
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the Biological Impact of Charge Distribution on a NTR1-Targeted Peptide.
Jia Y; Zhang W; Fan W; Brusnahan S; Garrison J
Bioconjug Chem; 2016 Nov; 27(11):2658-2668. PubMed ID: 27661393
[TBL] [Abstract][Full Text] [Related]
20. Imaging Neurotensin Receptor in Prostate Cancer With
Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z
Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]